Stimulator of interferon genes
Stimulator of interferon genes (STING), also known as transmembrane protein 173 (TMEM173), is a protein that in humans is encoded by the TMEM173 gene. STING plays a crucial role in the innate immune response to viral and bacterial infections, as well as in the regulation of the type I interferon pathway. This protein is involved in the recognition of cytosolic DNA and the activation of the transcription factor IRF3, leading to the production of interferon.
Function
STING is located in the endoplasmic reticulum and is activated upon binding to cyclic dinucleotides (CDNs), molecules that are often produced during microbial infections or generated in the cytosol of the host cell upon detection of DNA. Once activated, STING undergoes a conformational change and translocates from the endoplasmic reticulum to the Golgi apparatus. This translocation is essential for the recruitment of TANK-binding kinase 1 (TBK1) and the subsequent phosphorylation and activation of interferon regulatory factor 3 (IRF3). Activated IRF3 then translocates to the nucleus, where it induces the expression of type I interferons and other inflammatory cytokines.
Clinical Significance
Mutations in the TMEM173 gene have been associated with a range of autoimmune and autoinflammatory diseases, including STING-associated vasculopathy with onset in infancy (SAVI). Patients with SAVI exhibit symptoms such as systemic inflammation, skin lesions, and interstitial lung disease. This highlights the critical role of STING in controlling immune responses and maintaining immune homeostasis.
Furthermore, the STING pathway has been identified as a potential target for cancer immunotherapy. Activation of STING in tumor cells can lead to an antitumor immune response, making it a promising target for the development of new cancer treatments.
Research
Research on STING is focused on understanding its role in the innate immune response and its potential as a therapeutic target. Studies are exploring how STING signaling can be modulated to treat autoimmune diseases, cancer, and infectious diseases. Additionally, the development of small molecule STING agonists and antagonists is an area of active investigation.
See Also
References
<references />
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
